Atogepant and Clarithromycin (Macrol 500 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Strong CYP3A4 inhibition increases atogepant exposure.
Clinical significance and safety
Clarithromycin can increase atogepant exposure through strong CYP3A4 inhibition. Unlike ubrogepant, the atogepant label permits a specifically reduced regimen with strong inhibitors. The prescriber should review and adjust the regimen; this interaction is not a blanket contraindication.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.